Dong Yoon Kim, Seong-Min Hong, Jeong-Seok Cho, Sae-Byuk Lee, and Hyun-Dong Cho. Prev Nutr Food Sci 2024;29:321-31. https://doi.org/10.3746/pnf.2024.29.3.321

Background: Euonymus alatus (E. alatus) has traditionally been used for medicinal purposes, and its leaves are considered edible. While E. alatus is known for its diverse biological activities, the antioxidant, antidiabetic, and anticancer effects of its leaves extracted using different solvents have not been thoroughly investigated. Methods: This study examined the antioxidant, antidiabetic, anticancer, and life-prolonging effects of Euonymus alatus (E. alatus) leaf extract. Results: The phytochemical analysis showed that the ethanol extract contained the highest levels of polyphenols (347.2 mg/mL) and flavonoids (317.7 mg/mL) compared to the water and methanol extracts. In addition, specific phenolics, such as rutin, ellagic acid, and quercetin, were found in the ethanol extract. Antioxidant assays showed that the ethanol extract exhibited superior DPPH, ABTS radical, and H₂O₂-scavenging activities, as well as reducing power. In addition, the ethanol extract displayed strong α-glucosidase inhibitory activity in a dose-dependent manner. In cancer cell studies, the ethanol extract selectively inhibited the proliferation of MDA-MB-231 (breast) and LNCaP (prostate) cancer cells without affecting normal cells. Apoptosis induction was confirmed by nuclear condensation and increased caspase-3 activity. Furthermore, treatment with 30 mg/kg/day of the extract extended the lifespan of the tumor-bearing mice to 50 days, with no fatalities, indicating a dose-dependent protective effect. Conclusions: E. alatus leaf ethanol extract has potential as an antioxidant, antidiabetic, anticancer, and life-prolonging agent.

Age-related macular degeneration (AMD) is a leading cause of irreversible vision loss worldwide and is driven by complex pathophysiological processes, including oxidative stress, chronic inflammation, complement dysregulation, and vascular endothelial growth factor (VEGF)-mediated neovascularization. Nutritional interventions—particularly supplementation with carotenoids, omega-3 fatty acids, polyphenols, and essential micronutrients—have demonstrated clinical benefits in slowing disease progression, as evidenced by landmark trials such as AREDS and AREDS2. However, many AMD-relevant bioactives exhibit poor aqueous solubility, low chemical stability, and limited gastrointestinal bioavailability, which significantly constrain their therapeutic efficacy. Food-grade microgels have emerged as versatile colloidal delivery platforms capable of addressing these limitations through rational structural and physicochemical design. This review provides a systematic roadmap for developing food-grade microgels, organized into: (1) the molecular design of protein- and polysaccharide-based networks; (2) advanced fabrication strategies such as microfluidics and atomization; (3) spatiotemporal release programming within the gastrointestinal tract; and (4) multi-nutrient synergy for retinal protection. This approach highlights how controlled crosslinking, interfacial assembly, and tunable network architectures enhance nutrient stabilization. Particular emphasis is placed on spatiotemporal release programming within the gastrointestinal tract, including diffusion-limited gastric retention, pH- and bile-responsive swelling in the small intestine, and microbiota-triggered degradation in the colon. These mechanisms collectively enable region-specific release, improved micellar incorporation, enhanced systemic absorption, and more consistent retinal delivery. Furthermore, we discuss co-encapsulation strategies that accommodate both hydrophilic and lipophilic bioactives, thereby minimizing antagonistic interactions and enabling synergistic nutritional modulation of oxidative and inflammatory pathways implicated in AMD. A central novelty of this review is the integration of the gut–eye axis, framing microgel-based oral delivery as a systemic pathway to modulate retinal health via the intestinal environment. By bridging retinal disease biology with food colloid science, this review proposes food-grade microgels as a translational platform for next-generation nutraceutical interventions. The integration of programmable release behavior with clinically validated nutrient regimens offers a promising pathway toward more effective and mechanistically informed dietary management of AMD.

Lipid metabolism disorders such as hypercholesterolemia, hyperlipidemia, and hyperglycemia collectively characterize dyslipidemia, a condition marked by an imbalance in blood lipid levels and impaired lipid homeostasis. Policosanol, a mixture of long-chain alcohols derived from sugarcane, has been reported to improve lipid metabolism, but its cellular mechanisms remain underexplored. This study investigated the effects of policosanol (Reduchole22®) extracted using ethanol on lipid metabolism in HepG2 hepatocytes and Caco-2 enterocytes. The data were compared with atorvastatin, a widely used hyperlipidemia drug. Compared to the control group, 250-500 μg/mL of policosanol significantly reduced intracellular cholesterol and lipid accumulation via downregulating SREBP, ACAT, and APOB and upregulating LDL-receptor, ABCA1, and APOA1 in HepG2 cells. In addition, treatment of policosanol (250-500 μg/mL) markedly inhibited HMG-CoA reductase and ACAT2 expression, leading to decreased cholesterol and total lipid accumulation in Caco-2 cells. Moreover, policosanol suppressed H2O2-induced LDL oxidation in HepG2 cells, resulting in potential activity in preventing dyslipidemia. These findings suggest that policosanol (Reduchole22®) mediates cholesterol metabolism through mechanisms similar to atorvastatin. Moreover, it could be applied as a functional food ingredient for hyperlipidemia management in endogenous and exogenous cholesterol metabolism, providing a beneficial alternative in the food industry.

Alcoholic hepatic steatosis (AHS) is a common early-stage symptom of liver disease caused by alcohol consumption. Accordingly, several aspects of AHS have been studied as potential preventive and therapeutic targets. In this study, a novel strategy was employed to inhibit fatty liver accumulation and counteract AHS through the consumption of microorganism-fermented Protaetia brevitarsis larvae (FPBs). By using an AHS rat model, we assessed the efficacy of FPB by examining the lipid profile of liver/serum and liver function tests to evaluate lipid metabolism modulation. After FPB administration, the lipid profile—including high-density lipoprotein, total cholesterol, and total triglycerides—and histopathological characteristics exhibited improvement in the animal model. Interestingly, AHS amelioration via FPBs administration was potentially associated with poly-γ-glutamic acid (PγG), which is produced by Bacillus species during fermentation. These findings support the formulation of novel natural remedies for AHS through non-clinical animal studies, suggesting that PγG-enriched FPBs are a potentially valuable ingredient for functional foods, providing an ameliorative effect on AHS.